USANA Health Sciences (NYSE:USNA) Share Price Passes Above 200 Day Moving Average – Here’s What Happened

USANA Health Sciences, Inc. (NYSE:USNA) shares crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $19.43 and traded as high as $19.78. USANA Health Sciences shares last traded at $19.0660, with a volume of 89,336 shares traded.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on USNA. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research note on Friday, March 27th. Zacks Research lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Finally, Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, USANA Health Sciences has a consensus rating of “Reduce”.

USANA Health Sciences Stock Down 1.8%

The firm has a market capitalization of $351.96 million, a price-to-earnings ratio of 40.57, a P/E/G ratio of 0.76 and a beta of 0.76. The stock’s 50 day moving average price is $18.70 and its two-hundred day moving average price is $19.43.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.17. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. The business had revenue of $250.22 million for the quarter, compared to the consensus estimate of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, equities analysts expect that USANA Health Sciences, Inc. will post 2.12 EPS for the current fiscal year.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, insider Joshua Foukas sold 3,791 shares of the stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $19.82, for a total transaction of $75,137.62. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO G Doug Iiekking sold 5,360 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $18.75, for a total transaction of $100,500.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 13,716 shares of company stock valued at $257,276. 0.82% of the stock is owned by insiders.

Hedge Funds Weigh In On USANA Health Sciences

Several hedge funds have recently bought and sold shares of the business. Empowered Funds LLC increased its position in USANA Health Sciences by 9.7% during the first quarter. Empowered Funds LLC now owns 66,293 shares of the company’s stock worth $1,158,000 after buying an additional 5,856 shares during the last quarter. Lazard Asset Management LLC acquired a new position in USANA Health Sciences during the first quarter worth $1,265,000. Sei Investments Co. increased its position in USANA Health Sciences by 98.8% during the first quarter. Sei Investments Co. now owns 59,730 shares of the company’s stock worth $1,043,000 after buying an additional 29,691 shares during the last quarter. State of Wyoming acquired a new position in USANA Health Sciences during the first quarter worth $57,000. Finally, First Trust Advisors LP increased its position in USANA Health Sciences by 17.7% during the first quarter. First Trust Advisors LP now owns 14,784 shares of the company’s stock worth $258,000 after buying an additional 2,227 shares during the last quarter. 54.25% of the stock is owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.